CoChat
Sign Up
Cited by 245

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease.

Puchades, Maja, Hansson, Sara Folkesson, Nilsson, Carol L, Andreasen, Niels, Blennow, Kaj, Davidsson, Pia·2003·Molecular Brain Research
DOI 10.1016/j.molbrainres.2003.08.005
Open this paper in CoChat — free account

Abstract

By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD) patients and controls, it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD. Two-dimensional gel electrophoresis (2-DE), SYPRO Ruby staining and mass spectrometry were used for clinical screening of disease-influenced CSF proteins in AD patients compared to controls. In order to increase the detection of CSF proteins and to improve the separation of protein isoforms in a 2-D gel, micro-narrow range IPG strips were used. The levels of eight proteins and their isoforms, including apolipoprotein A1, apolipoprotein E, apolipoprotein J, beta-trace, retinol-binding protein, kininogen, alpha-1 antitrypsin, cell cycle progression 8 protein, and alpha-1beta glycoprotein were significantly altered in CSF of AD patients compared to controls. Furthermore, we also used liquid-phase IEF, as a prefractionation step, prior to 2-DE for comparison of CSF proteins between individual AD patients and controls. The levels of 37 proteins spots were altered in AD patients. One of the identified proteins, alpha-2-HS glycoprotein, has not previously been linked to AD. Our study shows that several glycoproteins are altered in AD.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.molbrainres.2003.08.005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. Andreasen, 1999, Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden. The Pitea Dementia Project, Neuroepidemiology, 18, 144, 10.1159/000026206 · DOI
  2. Andreasen, 2001, Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice, Arch. Neurol., 58, 373, 10.1001/archneur.58.3.373 · DOI · Paper page
  3. Bergamaschini, 1998, Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease, Alzheimer Dis. Assoc. Disord., 12, 102, 10.1097/00002093-199806000-00008 · DOI
  4. Bergamaschini, 2001, Activation of complement and contact system in Alzheimer's disease, Mech. Ageing Dev., 122, 1971, 10.1016/S0047-6374(01)00311-6 · DOI
  5. Choe, 2002, Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease, Electrophoresis, 23, 2247, 10.1002/1522-2683(200207)23:14<2247::AID-ELPS2247>3.0.CO;2-M · DOI
  6. Cockrell, 1988, Mini-Mental State Examination (MMSE), Psychopharmacol. Bull., 24, 689
  7. Davidsson, 2002, Identification of proteins in human cerebrospinal fluid using liquid phase isoelectric focusing as a prefractionation step followed by two-dimensional electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry, Rapid Commun. Mass Spectrom., 16, 2083, 10.1002/rcm.834 · DOI
  8. Davidsson, 2002, Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins, Brain Res. Mol. Brain Res., 109, 128, 10.1016/S0169-328X(02)00549-1 · DOI
  9. Davidsson, 2002, Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients, NeuroReport, 13, 611, 10.1097/00001756-200204160-00015 · DOI
  10. Edwards, 1997, Human CPR (cell cycle progression restoration) genes impart a Far-phenotype on yeast cells, Genetics, 147, 1063, 10.1093/genetics/147.3.1063 · DOI
  11. Folkesson Hansson, 2003, Validation of a prefractionation method followed by two-dimensional electrophoresis-applied to cerebrospinal fluid proteins from frontotemporal dementia patients, Proteomics
  12. Gollin, 1992, Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease, NeuroReport, 3, 201, 10.1097/00001756-199202000-00020 · DOI
  13. Hesse, 2000, Measurement of apolipoprotein E (apoE) in cerebrospinal fluid, Neurochem. Res., 25, 511, 10.1023/A:1007516210548 · DOI
  14. Jarvik, 1995, Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study, Neurology, 45, 1092, 10.1212/WNL.45.6.1092 · DOI
  15. Johnson, 1992, Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia, Appl. Theor. Electrophor., 3, 47
  16. Joseph, 1999, Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease, Immunopharmacology, 43, 203, 10.1016/S0162-3109(99)00136-8 · DOI
  17. Lidstrom, 2001, Normal levels of clusterin in cerebrospinal fluid in Alzheimer's disease, and no change after acute ischemic stroke, J. Alzheimer's Dis., 3, 435, 10.3233/JAD-2001-3501 · DOI
  18. Maury, 1987, Immunodetection of protein composition in cerebral amyloid extracts in Alzheimer's disease: enrichment of retinol-binding protein, J. Neurol. Sci., 80, 221, 10.1016/0022-510X(87)90156-0 · DOI
  19. McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  20. Merched, 2000, Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease, Neurobiol. Aging, 21, 27, 10.1016/S0197-4580(99)00103-7 · DOI
  21. Nishihara, 2002, Quantitative evaluation of proteins in one- and two-dimensional polyacrylamide gels using a fluorescent stain, Electrophoresis, 23, 2203, 10.1002/1522-2683(200207)23:14<2203::AID-ELPS2203>3.0.CO;2-H · DOI
  22. Raymackers, 2000, Electrophoresis, 21, 2266, 10.1002/1522-2683(20000601)21:11<2266::AID-ELPS2266>3.0.CO;2-Z · DOI
  23. Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol. Dis., 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
  24. Sickmann, 2000, Identification of proteins from human cerebrospinal fluid, separated by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis, 21, 2721, 10.1002/1522-2683(20000701)21:13<2721::AID-ELPS2721>3.0.CO;2-3 · DOI
  25. Sickmann, 2002, Towards a high resolution separation of human cerebrospinal fluid, J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 771, 167, 10.1016/S1570-0232(01)00626-2 · DOI
  26. Szweras, 2002, Alpha 2-HS glycoprotein/fetuin, a transforming growth factor-beta/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling, J. Biol. Chem., 277, 19991, 10.1074/jbc.M112234200 · DOI
  27. Yuan, 2002, Analysis of the human lumbar cerebrospinal fluid proteome, Electrophoresis, 23, 1185, 10.1002/1522-2683(200204)23:7/8<1185::AID-ELPS1185>3.0.CO;2-G · DOI

Cited by

Sorted by citations

Metadata

Authors
Puchades, M., Hansson, S. F., Nilsson, C. L., Andreasen, N., Blennow, K., & Davidsson, P.
Venue
Molecular Brain Research
Publisher
Elsevier BV
Published
2003-10
Volume
118
Issue
1-2
Pages
140-146
ISSN
0169-328X
DOI
10.1016/j.molbrainres.2003.08.005
Cited by
245
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review